QTTB Q32 Bio Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661998 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY176.6%
TTM EPS YoY210.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE24.0%
ROA18.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3.2%
Debt / equity0.00x
Current ratio56.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.62x
Accruals ratio29.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $53.74M | $0 | -$6.65M | $3.21M | $33.97M |
| R&D expense | $19.16M | $48.14M | $31.73M | $98.35M | $93.08M |
| SG&A expense | $17.68M | $17.96M | $9.88M | $38.14M | $36.84M |
| Operating income | $16.90M | -$66.10M | -$48.26M | -$133.28M | -$95.95M |
| Interest expense | — | — | $1.50M | — | — |
| Pretax income | $29.82M | -$46.09M | -$53.42M | $1.20M | -$95.76M |
| Income tax | $0 | $21,000 | $318,000 | $715,000 | $0 |
| Net income | $29.82M | -$47.73M | -$53.74M | -$5.00M | -$95.76M |
| EBITDA | $17.29M | -$65.61M | -$47.76M | -$131.99M | -$87.60M |
| EPS (basic) | 2.42 | -5.12 | -153.96 | -0.09 | -1.73 |
| EPS (diluted) | 2.42 | -6.58 | -153.96 | -0.09 | -1.73 |
| Weighted avg. shares (diluted) | 12.31M | 9.66M | 349,060 | 57.40M | 55.28M |
| Banking | |||||
| Net interest income | $1.05M | $2.83M | $693,000 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $48.30M | $78.61M | $31.26M | $49.54M | $108.38M |
| Short-term investments | — | $0 | $0 | $141.04M | $47.49M |
| Current assets | $55.05M | $81.88M | $28.72M | $181.01M | $191.91M |
| PP&E, net | $979,000 | $1.37M | $1.78M | $1.08M | $2.25M |
| Total assets | $61.78M | $92.33M | $47.06M | $228.47M | $211.72M |
| Current liabilities | $11.35M | $16.46M | $14.11M | $22.58M | $17.23M |
| Total liabilities | $19.76M | $86.66M | $118.53M | $50.49M | $42.07M |
| Shareholders' equity | $42.01M | $5.67M | -$182.92M | -$130.71M | $169.65M |
| Shares outstanding | 12.86M | 12.20M | 359,569 | 57.48M | 57.15M |
| Cash flow statement | |||||
| Operating cash flow | -$33.54M | -$67.72M | -$18.68M | -$113.66M | -$109.75M |
| Capital expenditure | $0 | $75,000 | $5,000 | $1.28M | $2.40M |
| Free cash flow | -$33.54M | -$67.79M | -$18.68M | -$114.95M | -$112.15M |
| Investing cash flow | $7.00M | $19.93M | -$5,000 | $36.72M | -$50.79M |
| Financing cash flow | -$3.12M | $95.14M | $406,000 | $596,000 | $52.17M |
| Depreciation & amortization | $391,000 | $487,000 | $499,000 | $1.29M | $8.35M |
| Stock-based compensation | $5.25M | $4.39M | $1.43M | $13.05M | $17.25M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.